Topical tazarotene: A review of its use in the treatment of plaque psoriasis

American Journal of Clinical Dermatology

Volumn 6, Issue 4, 2005, Pages 255-272

  Dando, Toni M ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DIFLORASONE DIACETATE; ETRETIN; ETRETINATE; FLUOCINONIDE; MOMETASONE FUROATE; TAZAROTENE;

BURNING SENSATION; CLINICAL TRIAL; CREAM; DERMATITIS; DESQUAMATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; MONOTHERAPY; OINTMENT; PAIN; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RASH; REVIEW; SKIN ATROPHY; TERATOGENICITY; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; COMBINED MODALITY THERAPY; HUMANS; KERATOLYTIC AGENTS; NICOTINIC ACIDS; PSORIASIS; RETINOIDS; ULTRAVIOLET THERAPY;

EID: 23844551754     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200506040-00006     Document Type: Review

References (57)

1. Lebwohl M. Psoriasis. Lancet 2003; 361 (9364): 1197-204
2. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8
3. Travis L, Weinberg JM. Medical backgrounder: psoriasis. Drugs Today 2002; 38 (12): 847-65
4. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm 2000; 57 (7): 645-62
5. Prussick R, Ebaugh BK. Psoriasis: an overview. Trauma 2003; 45 (4): 73-84
6. Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Investig Drugs 2001 May; 2 (5): 625-30
7. Endzweig-Gribetz CH, Brady C, Lynde C, et al. Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. J Cutan Med Surg 2002; 6 (3 Suppl.): 12-6
8. Allergan (US). Tazorac® (tazarotene topical cream): Prescribing information. Irvine (CA). 2001
9. Chandraratna RAS. Rational design of receptor-selective retinoids. J Am Acad Dermatol 1998 Oct; 39 Suppl. Pt 2: S124-8
10. Foster RH, Brogden RN, Benfield P. Tazarotene. Drugs 1998 May; 55: 705-11
11. Nagpal S, Patel S, Asano AT, et al. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor- responsive gene in skin. J Invest Dermatol 1996; 106 (2): 269-74
12. Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997; 109 (1): 91-5
13. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994; 30 (4): 581-90
14. Nagpal S, Thacher SM, Patel S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ 1996; 7: 1783-91
15. Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37: S18-24
16. Nagpal S, Athanikar J, Chandraratna AS. Separation of transactiviation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995; 270 (2): 923-7
17. Sebok B, Bonnekoh B, Kerenyi M, et al. Tazarotene induces epidermal cell differentiation in the mouse tail test used as an animal model for psoriasis. Skin Pharmacol Appl Skin Physiol 2000; 13 (5): 285-91
18. Kaidbey K, Kopper S, Sefton J. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Int J Dermatol 2001; 40: 468-71
19. Hecker D, Worsley J, Yueh G, et al. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999 Dec; 41 (6): 927-30
20. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000 Aug; 43 (2 Pt 3): S31-5
21. Tang-Liu DD-S, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999 Oct; 37: 273-87
22. Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol 1998 Oct; 39 Suppl. Pt 2: 134-8
23. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily corticofluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998 May; 38 (Pt 1): 705-11
24. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37 (1): 85-92
25. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003 May; 48 (5): 760-7
26. Allergan (US). Tazorac® (tazarotene topical gel): prescribing information. Irvine (CA). 2003
27. FDA. Medical review. Study #R168-121-8606: safety and efficacy of once-daily tazarotene (AGN 190168) 0.1% gel or 0.05% gel versus vehicle gel in stable plaque psoriasis [online]. Available from URL: http://www.fda.gov/cder/ [Accessed 2005 Mar 21]
28. FDA. Medical review. Study #R168-126-8606: safety, efficacy and duration of therapeutic effect of tazarotene (AGN 190168) 0.1% or 0.05% gel applied once daily versus lidex. 0.05% cream applied twice daily in stable plaque psoriasis [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Mar 21]
29. FDA. Medical review. Study #R168-145-8606: safety, efficacy and duration of therapeutic effect of once-daily tazarotene (AGN 190168) 0.1% gel or once-daily 0.05% gel versus twice-daily calcipotriol 0.005% ointment in plaque psoriasis: an investigator-masked study [online]. Available from URL: http:// www.fda.gov/cder [Accessed 2005 Mar 21]
30. FDA. Medical review. Study #R168-120-8606: safety, efficacy and duration of therapeutic effect of once-daily tazarotene (AGN 190168) 0.1% gel or 0.05% gel versus vehicle gel in stable plaque psoriasis [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Mar 21]
31. FDA. Medical review. Study #R168-125-8606: safety, efficacy and duration of therapeutic effect of tazarotene (AGN 190168) 0.1% or 0.05% gel applied once daily versus lidex® 0.05% cream applied twice daily in stable plaque psoriasis [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Mar 21]
32. FDA. Medical review. Multicenter, double-blind, randomized, vehicle-controled study of the safety and efficacy of 0.05% and 0.1% tazarotene creams applied once daily for 12 weeks, with a 12-week follow-up, in the treatment of plaque psoriasis (Study #190168-016C) [initiated 12/29/97, completed 1/22/99] [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Mar 10]
33. FDA. Medical review. Multicenter, double-blind, randomized, vehicle-controled study of the safety and efficacy of 0.05% and 0.1% tazarotene creams applied once daily for 12 weeks, with a 12-week follow-up, in the treatment of plaque psoriasis (Study #190168-017C) [initiated 12/30/97, completed 10/16/98] [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Mar 10]
34. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat 2004; 15: 27-9
35. FDA. Medical review: tazarotene gel [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Mar 10]
36. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002; 6 (2): 95-102
37. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998 Oct; 39 (Pt 1): 590-6
38. Gollnick H, Menter A. Combination therapy with tazarotene plus a topical cortico-steroid for the treatment of plaque psoriasis. Br J Dermatol 1999 Apr; 140 Suppl. 54: 18-23
39. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001 Mar; 40 (3): 210-2
40. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000 Oct; 22: 1225-38
41. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001 Jan; 40 (1): 64-6
42. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000 Nov; 43 (5 Pt 1): 821-8
43. Tzaneva S, Honigsmann H, Tanew A, et al. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002 Oct; 147 (4): 748-53
44. Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000 Mar; 42 (3): 493-5
45. Allergan Ltd (UK). Zorac 0.05% gel: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Oct 17]
46. Allergan Ltd (UK). Zorac 0.1% gel: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Oct 21]
47. Khachemoune A, Phillips TJ. Current treatment options in psoriasis. Hosp Pract (Off Ed) 2000; 35 (7): 93-107
48. van de Kerkhof PC. Textbook of psoriasis. Oxford: Blackwell Science Ltd, 1999
49. van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 2003; 16 (2): 69-83
50. Feldman S. Advances in psoriasis treatment. Dermatol Online J 2000 Sep; 6 (1): 4
51. Berson DS. Topical retinoids in primary care practice: CME [online]. Available from URL: http://www.medscape.com [Accessed 2005 May 20]
52. Lebwohl M, Ting PT, Koo JYM. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005; 64 Suppl. II: ii83-6
53. Connetics Corporation US. Soriatane® (acitretin) capsule: prescribing information [online]. Available from URL: http://www.soriatane.com/include/pi. pdf [Accessed 2004 May 20]
54. Minor SN, Monk BE. Zorac. Business Briefing: European Pharmacotherapy [online]. Available from URL: http://www.bbriefings.com/pdf/26/ ept032_t_allergan.pdf [Accessed 2005 Jul 20]
55. Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 2000 Jun; 42 (6): 1008-11
56. Lebwohl M, Ali S. Treatment of psoriasis: part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001 Oct; 45 (4): 487-98; quiz 499-502
57. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol 2003; 4 (3): 197-202